Form 4 Filing for BridgeBio Oncology Therapeutics, Inc.

This filing reports on a stock option grant to Neil Kumar, a director at BridgeBio Oncology Therapeutics, Inc. The option, designated as "Stock Option (Right to Buy)", was granted on June 16, 2026, with an exercise price of $7.73 per share. Mr. Kumar received 31,675 options, which carry the right to buy an equivalent number of Common Stock shares. These options vest in full on the earlier of the first anniversary of the grant date or the date of the next Annual Meeting of Stockholders, provided Mr. Kumar continues his service to the company. The filing also includes a Limited Power of Attorney, appointing specific individuals to execute SEC filings on behalf of Mr. Kumar, including Forms 3, 4, and 5, and Schedules 13D and 13G. This power of attorney remains in effect until Mr. Kumar is no longer required to file such forms or until it is revoked.